A large proportion
of HIV transmissions occur during recent infection or antiretroviral treatment
interruptions, Swiss investigators report in Clinical Infectious Diseases. Overall, 44% of transmissions were
associated with recent infection and 14% could be attributed to treatment
interruptions. The authors believe these findings represent a major challenge
for treatment as prevention (TasP) strategies.
“Our findings
imply that TasP needs to be accompanied by interventions to tackle treatment continuity,
adherence, retention in care, and, importantly, early diagnosis,” comment the
investigators.
Previous studies
have shown that between 10% and 80% of HIV transmissions are attributable to
patients who were recently infected with the virus. Knowing the proportion of
early phase transmissions is important, especially given the recent emphasis on
the use of HIV treatment as prevention.
Indeed, the impact
of treatment as prevention on the ongoing epidemic could be limited if a high
proportion of transmissions originate in individuals with recent infection. A
high proportion of such patients are unaware of their status and are therefore
unable to benefit from HIV therapy. Moreover, because recent infection is
associated with a very high viral load, individuals with this phase of
infection are often highly infectious.
Investigators from
the Swiss HIV Cohort Study therefore conducted a retrospective analysed of the
genetic characteristics of stored blood samples obtained from Swiss HIV
patients. Using a technique called phylogenetic analysis, they looked for
infections with similar genetic profiles which were likely to be part of a
transmission cluster.
A total of 19,604
genetic sequences from approximately 11,000 patients (59% of cohort
participants) were available for analysis.
The year of HIV
diagnosis for patients included in the analysis ranged from 1984 to 2014. Most
(71%) were men, 77% were white and 38% were in the men who have sex with men
(MSM) risk group.
Date of HIV
seroconversion could be estimated for 4079 patients, and 82% of these
individuals were diagnosed in the first year after seroconversion.
The investigators
identified between 71 and 378 transmission pairs. Approximately two-thirds
(62%-66%) involved MSM.
When recent
infection was defined as the first year after infection, the median percentage
of transmissions attribution to recent infection ranged from a low of 41% to a
high of 44%. Using six months since seroconversion as the criterion for recent
infection showed that between 28%-42% of transmissions had their source in
patients with recent infection.
The authors then
looked at transmissions during the chronic phase of HIV infection.
Higher viral load
(p < 0.001), lower CD4 count (p = 0.04),
and longer time to initiation of antiretroviral treatment (p = 0.005)
were all associated with transmissions.
Some 54 of the 121
people who transmitted HIV in the chronic-phase (45%) were known to have started HIV therapy. Viral
load data were available for 44 of these individuals, and 35 had at least one
measurement above 400 copies/ml (median detectable viral load, 70,800
copies/ml). The authors suggest the other nine patients could represent
non-direct transmission pairs (for example, an intermediate transmitter), a
false-positive cluster, or a missed detectable viral load measurement.
Additional data
were obtained for the 35 people with a confirmed viral-load who transmitted in the chronic phase. For 18, the
estimated data of transmission was very close to the date HIV therapy was
initiated. “These individuals transmitted either briefly before or briefly
after ART initiation”, suggest the authors.
All but one of the
other 17 patients had a documented antiretroviral treatment interruption.
“Overall, these
results indicate that a substantial fraction of chronic-phase transmission events
– at least 17 of 121 (14%) and up to 54 of 121 (45%) – occurred after ART
initiation by the transmitter,” comment the investigators. “This observation
underlines the important contribution of treatment interruptions and the
periods close to ART initiation for onward HIV transmission.”
They conclude, “our
work highlights the high fraction of recent-phase transmission and transmission
during therapy interruptions, two key challenges for curbing HIV incidence with
TasP.”